MX2018001486A - Derivados de etinilo. - Google Patents

Derivados de etinilo.

Info

Publication number
MX2018001486A
MX2018001486A MX2018001486A MX2018001486A MX2018001486A MX 2018001486 A MX2018001486 A MX 2018001486A MX 2018001486 A MX2018001486 A MX 2018001486A MX 2018001486 A MX2018001486 A MX 2018001486A MX 2018001486 A MX2018001486 A MX 2018001486A
Authority
MX
Mexico
Prior art keywords
lower alkyl
halogen
substituted
pyridinyl
pyrimidinyl
Prior art date
Application number
MX2018001486A
Other languages
English (en)
Inventor
Ricci Antonio
Jaeschke Georg
Vieira Eric
Rueher Daniel
Plancher Jean-Marc
O'hara Fionn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018001486A publication Critical patent/MX2018001486A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) en donde R1 es hidrógeno, F o Cl; L es un enlace o alquileno inferior; R2 es -(CH2)nO-alquiio inferior, alquilo inferior sustituido por halógeno, -(CH2)nC(O)O-alquiio inferior, fenilo sustituido por alquilo inferior o halógeno, o es un grupo heteroarilo de 5 o 6 miembros, seleccionado entre piridinilo, pirimidinilo, piridazinilo, tiazolilo, imidazolilo, pirazolilo o triazolilo, que están opcionalmente sustituidos por alquilo inferior, halógeno, alcoxi inferior, =O, benciloxi, cicioalcoxi, hidroxi, ciano, alquilo inferior sustituido por halógeno, o por -(CH2)nO-aiquilo inferior; n es 1, 2 o 3; R3 es hidrógeno, alquilo inferior o -(CH2)nO-alquilo inferior; R4 es fenilo, piridinilo o pirimidinilo, opcionalmente sustituido por F; Y es CF o CCl; o a una sal farmacéuticamente aceptable o sal de adición ácida, a una mezcla racémica, o a su correspondiente enantiómero y/o isómero óptico y/o estereoisómeros de los mismos. Los compuestos se pueden usar para el tratamiento de la enfermedad de Parkinson, ansiedad, emesis, trastorno obsesivo compulsivo, autismo, neuroprotección, cáncer, depresión y diabetes tipo 2.
MX2018001486A 2015-08-03 2016-08-02 Derivados de etinilo. MX2018001486A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179550 2015-08-03
PCT/EP2016/068359 WO2017021384A1 (en) 2015-08-03 2016-08-02 Ethynyl derivatives

Publications (1)

Publication Number Publication Date
MX2018001486A true MX2018001486A (es) 2018-03-15

Family

ID=53776452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001486A MX2018001486A (es) 2015-08-03 2016-08-02 Derivados de etinilo.

Country Status (21)

Country Link
US (1) US10011607B2 (es)
EP (1) EP3331882B1 (es)
JP (1) JP6975511B2 (es)
KR (1) KR20180030857A (es)
CN (1) CN107667107B (es)
AR (1) AR105556A1 (es)
AU (1) AU2016302696B2 (es)
BR (1) BR112017023951A2 (es)
CA (1) CA2983908A1 (es)
CL (1) CL2018000278A1 (es)
CO (1) CO2017011010A2 (es)
HK (1) HK1246790A1 (es)
IL (1) IL255103B (es)
MX (1) MX2018001486A (es)
PE (1) PE20180357A1 (es)
PH (1) PH12018500247A1 (es)
RU (1) RU2722014C9 (es)
TW (1) TWI621619B (es)
UA (1) UA120888C2 (es)
WO (1) WO2017021384A1 (es)
ZA (1) ZA201707015B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
ES2791496T3 (es) 2015-08-03 2020-11-04 Glenmark Pharmaceuticals Sa Compuestos novedosos como moduladores de ROR gamma
BR112018001960A2 (pt) 2015-08-03 2018-09-18 Bristol-Myers Squibb Company compostos heterocíclicos úteis como moduladores de tnf alfa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780128A1 (en) * 2009-11-06 2011-05-12 P. Jeffrey Conn Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
KR101576343B1 (ko) * 2011-04-26 2015-12-09 에프. 호프만-라 로슈 아게 피라졸리딘-3-온 유도체
MA38885B1 (fr) * 2013-09-25 2018-11-30 Hoffmann La Roche Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
MA39305A3 (fr) * 2014-02-25 2018-05-31 Hoffmann La Roche Dérivés d'éthynyle

Also Published As

Publication number Publication date
AU2016302696A1 (en) 2017-11-02
AR105556A1 (es) 2017-10-18
CN107667107A (zh) 2018-02-06
TW201718589A (zh) 2017-06-01
UA120888C2 (uk) 2020-02-25
KR20180030857A (ko) 2018-03-26
IL255103B (en) 2020-01-30
JP6975511B2 (ja) 2021-12-01
HK1246790A1 (zh) 2018-09-14
US10011607B2 (en) 2018-07-03
EP3331882B1 (en) 2020-04-29
PE20180357A1 (es) 2018-02-21
CO2017011010A2 (es) 2018-02-09
IL255103A0 (en) 2017-12-31
PH12018500247A1 (en) 2018-08-13
JP2018522037A (ja) 2018-08-09
CA2983908A1 (en) 2017-02-09
BR112017023951A2 (pt) 2018-07-24
RU2018105872A (ru) 2019-09-05
TWI621619B (zh) 2018-04-21
WO2017021384A1 (en) 2017-02-09
ZA201707015B (en) 2018-11-28
EP3331882A1 (en) 2018-06-13
CN107667107B (zh) 2021-05-18
US20180127429A1 (en) 2018-05-10
RU2722014C2 (ru) 2020-05-26
AU2016302696B2 (en) 2020-05-07
RU2722014C9 (ru) 2020-10-22
RU2018105872A3 (es) 2019-12-26
CL2018000278A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
PH12018500247A1 (en) Ethynyl derivatives
PH12016500427A1 (en) Ethynyl derivatives
PH12016501100A1 (en) Ethynyl-imidazolin-2, 4-dione derivatives as mglur4 modulators
BR112012015168A2 (pt) "derivados de benzamida substituída".
PH12015500400A1 (en) 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MX2016008536A (es) Derivados de fluoro-naftilo.
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
EA201391815A1 (ru) Замещенные производные бензамида
MX338631B (es) 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MX2016016488A (es) Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
PH12016501481B1 (en) Ethynyl derivatives
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
PH12019500119A1 (en) Ethynyl derivatives
MY165141A (en) Pyrazolidin-3-one derivatives
PH12015500261A1 (en) Arylethynyl pyrimidines
AR075898A1 (es) Derivados de amida como ligandos del receptor y5 del neuropeptido.
MX2010002585A (es) Derivados de piperidina como antagonistas del receptor nk3.
MX2009013116A (es) Derivados de prolinamida-tetrazol como antagonistas del receptor nk3.
TH127359B (th) อนุพันธ์ 1,2,4-ไตรอะโซโล[4,3-a]ไพริดีนและการใช้มันในฐานะโพสิทิฟ อัลโลสเตริก มอดูเลเตอร์ ของหน่วยรับความรู้สึก MGLUR2

Legal Events

Date Code Title Description
FG Grant or registration